What is Cosmo Pharmaceuticals NV Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cosmo Pharmaceuticals NV's annualizedGross Profit for the quarter that ended in Dec. 2023 was CHF92.71 Mil.
Cosmo Pharmaceuticals NV's average Total Assets over the quarter that ended in Dec. 2023 was CHF620.61 Mil. Therefore, Cosmo Pharmaceuticals NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 14.94%.
Cosmo Pharmaceuticals NV Gross-Profit-to-Asset % Historical Data
The historical data trend for Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset %
For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is two times the semi-annual (Dec. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Cosmo Pharmaceuticals NV Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:COPN has been successfully added to your 